Patent 10143704 was granted and assigned to Epizyme on December, 2018 by the United States Patent and Trademark Office.
The present invention relates to DOT1L inhibitors. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.